Anti-inflammatory effects of levosimendan in decompensated heart failure: Impact on weight loss and anemia

American Journal of Cardiology

Volumn 95, Issue 7, 2005, Pages 923-924

  Parissis, John T ^a   Farmakis, Dimitrios ^a   Kremastinos, Dimitrios T ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

LEVOSIMENDAN;

ANEMIA; ANTIINFLAMMATORY ACTIVITY; BLOOD VOLUME; BONE MARROW; CACHEXIA; CIRCULATION; CLINICAL OBSERVATION; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG INFUSION; DRUG RESPONSE; HEART FAILURE; HEART MUSCLE CONTRACTILITY; HEMOCONCENTRATION; HEMODYNAMICS; HUMAN; NOTE; PATIENT; PRIORITY JOURNAL; VASODILATATION; WEIGHT REDUCTION;

EID: 15244358414     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2004.11.018     Document Type: Letter

References (4)

1. M. Kivikko, S. Antila, J. Eha, L. Lehtonen, P.J. Pentikainen Pharmacodynamics and safety of a new calcium sensitizer, levosimendan, and its metabolites during an extended infusion in patients with severe heart failure J Clin Pharmacol 42 2002 43 51
2. J.T. Parissis, S. Adamopoulos, C. Antoniades, G. Kostakis, A. Rigas, S. Kyrzopoulos, E. Iliodromitis, D. Kremastinos Effects of levosimendan on circulating pro-inflammatory cytokines and soluble apoptosis mediators in patients with decompensated advanced heart failure Am J Cardiol 93 2004 1309 1312
3. S. von Haehling, G.P. Diller, S.D. Anker Impact of levosimendan treatment on chronic heart failure [letter] Am J Cardiol 94 2004 1105
4. P. Poder, J. Eha, S. Sundberg, S. Antila, M. Heinpalu, I. Loogna, U. Planken, S. Rantanen, L. Lehtonen Pharmacodynamics and pharmacokinetics of oral levosimendan and its metabolites in patients with severe congestive heart failure: a dosing interval study J Clin Pharmacol 44 2004 1143 1150